The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Brian B. Hasinoff

Faculty of Pharmacy

Apotex Centre

University of Manitoba

750 McDermot Avenue

Canada. Electronic address:

[email]@umanitoba.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Faculty of Pharmacy, Apotex Centre, University of Manitoba, 750 McDermot Avenue, Canada. Electronic address:. 1997 - 2012
  • Apotex Centre, University of Manitoba, Winnipeg, Canada. 2010

References

  1. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Hasinoff, B.B., Wu, X., Nitiss, J.L., Kanagasabai, R., Yalowich, J.C. Biochem. Pharmacol. (2012) [Pubmed]
  2. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Hasinoff, B.B., Patel, D. Cardiovasc. Toxicol. (2010) [Pubmed]
  3. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Hasinoff, B.B. Toxicol. Appl. Pharmacol. (2010) [Pubmed]
  4. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Hasinoff, B.B., Patel, D. Toxicol. Appl. Pharmacol. (2010) [Pubmed]
  5. The iron chelator Dp44mT does not protect myocytes against doxorubicin. Hasinoff, B.B., Patel, D. J. Inorg. Biochem. (2009) [Pubmed]
  6. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Hasinoff, B.B., Patel, D., O'Hara, K.A. Mol. Pharmacol. (2008) [Pubmed]
  7. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Hasinoff, B.B. Expert. Opin. Investig. Drugs (2008) [Pubmed]
  8. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. Liang, H., Wu, X., Yalowich, J.C., Hasinoff, B.B. Mol. Pharmacol. (2008) [Pubmed]
  9. The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Hasinoff, B.B., Liang, H., Wu, X., Guziec, L.J., Guziec, F.S., Marshall, K., Yalowich, J.C. Bioorg. Med. Chem. (2008) [Pubmed]
  10. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Hasinoff, B.B., Patel, D., Wu, X. Cardiovasc. Toxicol. (2007) [Pubmed]
  11. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Hasinoff, B.B., Herman, E.H. Cardiovasc. Toxicol. (2007) [Pubmed]
  12. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Hasinoff, B.B., Wu, X., Begleiter, A., Guziec, L.J., Guziec, F., Giorgianni, A., Yang, S., Jiang, Y., Yalowich, J.C. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  13. Dexrazoxane use in the prevention of anthracycline extravasation injury. Hasinoff, B.B. Future. Oncology. (london,. England) (2006) [Pubmed]
  14. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Hasinoff, B.B., Wu, X., Yalowich, J.C., Goodfellow, V., Laufer, R.S., Adedayo, O., Dmitrienko, G.I. Anticancer. Drugs (2006) [Pubmed]
  15. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. Hasinoff, B.B., Begleiter, A. Free Radic. Res. (2006) [Pubmed]
  16. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Hasinoff, B.B., Wu, X., Krokhin, O.V., Ens, W., Standing, K.G., Nitiss, J.L., Sivaram, T., Giorgianni, A., Yang, S., Jiang, Y., Yalowich, J.C. Mol. Pharmacol. (2005) [Pubmed]
  17. The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. Hasinoff, B.B. J. Inorg. Biochem. (2003) [Pubmed]
  18. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Hasinoff, B.B., Schroeder, P.E., Patel, D. Mol. Pharmacol. (2003) [Pubmed]
  19. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Hasinoff, B.B., Schnabl, K.L., Marusak, R.A., Patel, D., Huebner, E. Cardiovasc. Toxicol. (2003) [Pubmed]
  20. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II. Hasinoff, B.B., Takeda, K., Ferrans, V.J., Yu, Z.X. Anticancer. Drugs (2002) [Pubmed]
  21. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Hasinoff, B.B., Abram, M.E., Barnabé, N., Khélifa, T., Allan, W.P., Yalowich, J.C. Mol. Pharmacol. (2001) [Pubmed]
  22. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. Hasinoff, B.B., Abram, M.E., Chee, G.L., Huebner, E., Byard, E.H., Barnabé, N., Ferrans, V.J., Yu, Z.X., Yalowich, J.C. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  23. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Hasinoff, B.B., Chee, G.L., Thampatty, P., Allan, W.P., Yalowich, J.C. Anticancer. Drugs (1999) [Pubmed]
  24. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). Hasinoff, B.B., Aoyama, R.G. Chirality (1999) [Pubmed]
  25. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane. Hasinoff, B.B., Tran, K.T. J. Inorg. Biochem. (1999) [Pubmed]
  26. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Hasinoff, B.B., Kuschak, T.I., Creighton, A.M., Fattman, C.L., Allan, W.P., Thampatty, P., Yalowich, J.C. Biochem. Pharmacol. (1997) [Pubmed]
 
WikiGenes - Universities